BNET Industries
Market Cap:$231.7M
Last Fiscal Year Sales:$28.7M
- Public
- US
Dow Jones Description
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of oncology and other drug candidates that meet critical health challenges for which there are few other treatment options. The Company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. Spectrum's passion to identify, develop and deliver better options for people suffering from cancer is behind every action they take. At Spectrum, everyone is committed to excellence and strives to make a difference every day.
Number of Employees 84
Contact Information
157 Technology Dr
Irvine, California 92618-2402
(949) 788-6700
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Spectrum Pharmaceuticals and Handok sign collaboration agreement
-
Drug Maker Spectrum Signs Deal With Japanese Company
-
Spectrum touts increase in Zevalin sales
-
Spectrum Pharmaceuticals, Inc. SPPI JOBS Inks Deal with Korea's Handok Pharmaceuticals for Cancer Drug; Handok...
-
UPDATE 2-Spectrum says CMS OKs reimbursement of its cancer drug
-
Spectrum Pharmaceuticals Secures $50 Million from Institutional Investors
-
Unusual 11 Mid-Day Movers 9/8: OPXA, ITLN, CBY, ORH Higher; OSIR, UBSH, EXXI, SPPI Lower
-
Morgan Joseph Downgrades Spectrum Pharmaceuticals SPPI to Hold
-
PREVIEW-Spectrum's cancer drug expected to cross FDA hurdle
-
Spectrum Pharmaceuticals reports Q2 net loss
-
Spectrum Pharma Provides FDA With Addl. Details For Cancer Drug Zevalin - Update
-
Spectrum Pharmaceuticals, Inc. SPPI Receives $10 Million from Two Institutional Investors at $5.83 Per Share
News & Analysis
Filter by
m. e. garza and spectrum pharmaceuticals inc. - All News and Analysis
Spectrum Pharma: Market Opportunities for Zevalin May Expand Significantly
Seeking Alpha
- 2009-09-13
Following the presentation by Spectrum Pharmaceuticals SPPI, which was held in front of a standing room only crowd of institutional investors, hedge fund managers and Wall Street banker types at the Rodman & Renshaw Healthcare Conference in New York, Dr. Andrew Sandler was mobbed with questions from members of the...
Spectrum Pharmaceuticals, Sequenom Shares Rise on Heavy Volume
Seeking Alpha
- 2009-09-01
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) jumped on twice the average volume Monday. Shares for the biopharmaceutical company, which focuses on pioneering novel cancer therapies with a focus primarily in the areas of hematology-oncology and urology, are under a heavy accumulation which is related to Spectrum’s dealings with the FDA,...
More Positive Developments for Spectrum Pharma
Seeking Alpha
- 2009-08-06
Spectrum Pharmaceuticals, Inc. SPPI, the biotechnology company with a primary focus in oncology, today announced that it has acquired 100% rights to RenaZorb®, a novel compound, being developed for chronic kidney disease - which is also a family of compounds represented by SPI-014, also known as RZB-014). The lanthanum-based...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
Presented by American Express